Autophagy in diabetic nephropathy: a review.

Elias A T Koch, Rola Nakhoul, Farid Nakhoul, Nakhoul Nakhoul

Journal: International urology and nephrology 2021;52(9):1705-1712

PMID: 32661628

Abstract

Diabetes mellitus (DM) is the leading cause of end stage renal disease. 40% of the patients worldwide will require replacement therapy after 20 years of DM worldwide. Early-stage diabetic nephropathy is characterized by hyperfiltration related to hypeglycemia-induced afferent artery vasodilatation with micro-and macroalbuminuria. Later on, proteinuria with arterial hypertension may appear, culminating in glomerular filtration rate (GFR) decline and end stage renal disease. Forty percent of diabetic patients develop microvascular and macrovascular complications, with increased risk among patients with genetic predisposition, such as Haptoglobin 2-2 phenotype. The most frequent complications in the daily clinical practice are diabetic kidney disease, diabetic retinopathy and vascular disease, such as coronary artery disease and stroke. Various pathways are involved in the pathogenesis of diabetic kidney disease. Chronic systemic inflammation and the inflammatory response, such as increased circulating cytokines (Interleukins), have been recognized as main players in the development and progression of diabetic kidney disease. DM is also associated with increased oxidative stress, and alterations in carbohydrate, lipid and protein metabolism. Overexpression of the renin-angiotensin-aldosterone system (RAAS) in the kidney, the vitamin D-Vitamin D receptor-klotho axis, and autophagy. Differences in the ATG5 protein levels or ATG5 gene expression involved in the autophagy process have been associated with diabetic complications such as diabetic kidney disease. Under normal blood glucose level, autophagy is an important protective mechanism in renal epithelial cells, including podocytes, proximal tubular, mesangial and endothelial cells. Down regulation of the autophagic mechanism, as in hyperglycemic condition, can contribute to the development and progression of diabetic kidney disease.

Address: Department of Dermatology, University Hospital, Erlangen, Germany.; Division of Nephrology and Hypertension, Diabetes and Metabolism Lab, Azrieli Faculty of Medicine in Galilee, Baruch Padeh Poriya Medical Center, Lower galilee 15208, Ramat-Gan, Israel.; Division of Nephrology and Hypertension, Diabetes and Metabolism Lab, Azrieli Faculty of Medicine in Galilee, Baruch Padeh Poriya Medical Center, Lower galilee 15208, Ramat-Gan, Israel. [email protected].; Azrieli Faculty of Medicine in the Galilee, Bar Ilan University, Safed, Israel. [email protected].; Bar-Ilan University, Ramat-Gan, Israel. [email protected].; Ophtalmology Division, Baruch Padeh Poriya, Lower Galilee, Israel.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.